Local Neuroinflammation and the Progression of Alzheimer's Disease

References

• Aisen PS, Davis KL, et al (2000). A randomized controlled trial of prednisone in Alzheimer's disease. Neurology 54: 588–593.
   PubMed Web of Science ®Google Scholar
• Akiyama H, Yamada T, et al (1991). Association of amyloid P component with complement proteins in neurologi-cally diseased tissue. Brain Res 548: 349–352.
   PubMed Web of Science ®Google Scholar
• Alldred A (2001). Etanercept in rheumatoid arthritis. Exp Opin Pharmacother 1: 1137–1148.
   Google Scholar
• Asensio VC, Campbell IL (1999). Chemokines in the CNS: plurifunctional mediators in diverse states. Trends Neu-rosci 22: 504–512.
   PubMed Web of Science ®Google Scholar
• Bacon KB, Harrison JK (2000). Chemokines and their re-ceptors in neurobiology: perspectives in physiology and homeostasis. J Neuroimmunol 104: 92–97.
   PubMed Web of Science ®Google Scholar
• Baik EJ, Kim EJ, et al (1999). Cyclooxygenase-2 selective in-hibitors aggravate kainic acid induced seizure and neu-ronal cell death in the hippocampus. Brain Res 843: 118–129.
   PubMed Web of Science ®Google Scholar
• Blacker D, Wilcox MA, et al (1998). Alpha-2-macroglobulin is genetically associated with Alzheimer's disease. Nat Genet 19: 357–360.
   PubMed Web of Science ®Google Scholar
• Broe GA, Grayson DA, et al (2000). Anti-inflammatory drugs protect against Alzheimer's disease at low doses. Arch Neurol 57: 1586–1591.
   PubMed Web of Science ®Google Scholar
• Cacebelos R, Alvarez XA, et al (1994). Brain interleukin-1 beta in Alzheimer's disease and vascular dementia. Methods Find Exp Clin Pharmacol 16: 141–145.
   Google Scholar
• Chapman GA, Moores K, et al (2000). Fractalkine cleavage from neuronal membranes represents an acute event in the inflammatory response to excitotoxic brain damage. J Neurosci 20: 2–6.
   Google Scholar
• Collin JS, Perry RT, et al (2000). Association of a haplo-type for tumor necrosis factor in siblings with late-onset Alzheimer's disease: the NIMH Alzheimer's disease ge-netics initiative. Am J Med Genet 96: 823–830.
   Google Scholar
• Dickson DW, Lee SC, et al (1993). Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia 7: 75–83.
   PubMed Web of Science ®Google Scholar
• Du Y, Dodel RC, et al (2000). Association of an interleukin 1 alpha polymorphism with Alzheimer's disease. Neu-rology 55: 480–483.
   Google Scholar
• Eikelenboom P, Hack CE, et al (1989). Complement ac-tivation in amyloid plaques in Alzheimer's dementia. Virchows Arch Cell Pathol 56: 259–262.
   Google Scholar
• Ferreira SH, Moncada S, Vane JR (1973). Prostaglandins and the mechanism of analgesia produced by aspirin-like drugs. Brit j Pharmacol 49: 86–97.
   PubMed Web of Science ®Google Scholar
• Fiane AE, Mollnes TE, et al (1999). Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts. Xenotransplantation 6: 52–65.
   PubMed Web of Science ®Google Scholar
• Furlong ST, Dutta AS, et al (2000). C3 activation is in-hibited by analogs of compstatin but not by serine protease inhibitors or peptidyl alpha-ketoheterocycles. /mmunopharmaco/ogy 48: 199–212.
   PubMedGoogle Scholar
• Griffin WST, Stanley LC, et al (1989). Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syn-drome and Alzheimer's disease. Proc Soc Nati Acad Sci USA 86: 7611–7615.
   PubMed Web of Science ®Google Scholar
• Grimaldi LM, Casadei VM, et al (2000). Association of early-onset Alzheimer's disease with an interleukin-1a gene polymorphism. Ann Neurol 47: 361–365.
   PubMed Web of Science ®Google Scholar
• Hamilton K, Clair EW (2000). Tumour necrosis factor-alpha blockade: a new era for the effective management of rheumatoid arthritis. Exp Opin Pharmacother 1: 1041–1052.
   PubMedGoogle Scholar
• Haymaker W, Adams RD (eds) (1982). Histology and histopathology of the nervous system. Charles C Thomas: Springfield, IL, pp 1150–1173.
   Google Scholar
• Hesselgesser J, Horuk R (1999). Chemokine and chemokine receptor expression in the central nervous system. JNeu-rovirol 5: 13–26.
   Google Scholar
• Hicks PS, Saunero-Nazia L, et al (1992). Serum amyloid P component binds to histones and activates the classical complement pathway. J Immunol 149: 3689–3694.
   Google Scholar
• Hope HR, Remsen EE, et al (2000). Large-scale purifica-tion of myeloperoxidase from KL60 promyelocytic cells: characterization and comparison to human neutrophil myeloperoxidase. Protein Expr Purif 18: 269–276.
   Google Scholar
• Ishii T, Haga S (1984). Immuno-electron-microscopic lo-calization of complements in amyloid fibrils of senile plaques. Acta Neuropathol (Berlin) 63: 296–300.
   PubMed Web of Science ®Google Scholar
• Itagaki S, Akiyama H, et al (1994). Ultrastructural lo-calization of complement membrane attack complex (MAC)-like immunoreactivity in brains of patients with Alzheimer's disease. Brain Res 645: 78–84.
   PubMed Web of Science ®Google Scholar
• Jiang H, Robey F, et al (1992). Localization of sites through which C-reactive protein binds to and activates comple-ment to residues 14–26 and 76–92 of the human C1q A chain. J Exp Med 175: 1373–1379.
   Google Scholar
• Kamboh MI, Aston CE, et al (1997). Genetic effect of alpha-1-antichymotrypsin on the risk of Alzheimer's disease. Genomics 40: 382–384.
   PubMed Web of Science ®Google Scholar
• Kaufmann VVE, Worley PF, et al (1996). COX-2, a synapti-cally induced enzyme, is expressed by excitatory neu-rons at post-synaptic sites in rat cerebral cortex. Proc Nati Acad Sci USA 93: 2317–2321.
   PubMed Web of Science ®Google Scholar
• Klegeris A, McGeer PL (2000). Interaction of various intra-cellular signaling mechanisms involved in mononuclear phagocyte toxicity toward neuronal cells. J Leukoc Biol 67: 127–133.
   PubMed Web of Science ®Google Scholar
• Klegeris A, Walker DG, et al (1999). Toxicity of human THP-1 monocytic cells towards neuron-like cells is reduced by non-steroidal anti-inflammatory drugs (NSAIDs). Neuropharmaco/ogy 38: 1017–1025.
   PubMed Web of Science ®Google Scholar
• Lagrand WK, Visser CA, et al (1999). C-reactive protein as a cardiovascular risk factor. Circulation 100: 96–102.
   PubMed Web of Science ®Google Scholar
• Lambris DH (1993). The chemistry, biology, and phylogeny of C3. In: Complement today. Cruise JM, LLewis RE Jr (eds). Karger: Basel, pp 16–45.
   Google Scholar
• Licastro F, Pedrini S, et al (2000a). Polymorphisms of the IL-6 gene increase the risk for late onset Alzheimer's disease and affect IL-6 plasma levels. Neurobiol Aging 21(1S): S38.
   Google Scholar
• Licastro F, Pedrini S, et al (2000b). Gene polymorphism affecting a1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk. Ann Neurol 48: 388–391.
   PubMed Web of Science ®Google Scholar
• Lieberman AP, Pitha PM, et al (1989). Production of tumor necrosis factor and other cytokines by astrocytes stim-ulated with lipopolysaccharide or a neurotropic virus. Proc Natl Acad Sci USA 86: 6348–6352.
   PubMed Web of Science ®Google Scholar
• MacKenzie IRA (2000). Anti-inflammatory drugs and Alzheimer-type pathology in aging. Neurology 54: 732–734.
   Google Scholar
• McCusker SM (2001). Association between polymorphism in regulatory region of gene encoding tumour necro-sis factor A and risk of Alzheimer's disease and vas-cular dementia: a case-control study. Lancet 357: 436–439.
   PubMed Web of Science ®Google Scholar
• McGeer EG, Yasojima K, et al (2001). Inflammation in the pathogenesis of Parkinson's disease. BC Med 143: 138–141.
   Google Scholar
• McGeer PL (2000). Cyclooxygenase-2 inhibitors: rationale and therapeutic potential for Alzheimer's disease. Drugs Aging 17: 1–11.
   PubMed Web of Science ®Google Scholar
• McGeer PL, Akiyama H, et al (1989). Immune system re-sponse in Alzheimer's disease. Can J Neurol Sci 16: 516–527.
   PubMed Web of Science ®Google Scholar
• McGeer PL, Harada N, et al (1992). Prevalence of dementia amongst elderly Japanese with leprosy: apparent effect of chronic drug therapy. Dementia 3: 146–149.
   Google Scholar
• McGeer PL, McGeer EG (1995). The inflammatory response system of brain: implications for therapy of Alzheimer's and other neurodegenerative diseases. Brain Res Rev 21: 195–218.
   PubMed Web of Science ®Google Scholar
• McGeer PL, McGeer EG (2000). Autotoxicity and Alzheimer's disease. Arch Neurol 57: 789–790.
   PubMedGoogle Scholar
• McGeer PL, McGeer EG (2001). Polymorphisms in inflam-matory genes enhance the risk of Alzheimer's disease. Arch Neurol 58: 1790–1792.
   PubMed Web of Science ®Google Scholar
• McGeer PL, Rogers J, et al (1990). Anti-inflammatory drugs and Alzheimer's disease? Lancet 335,1037.
   Google Scholar
• McGeer PL, Schulzer M, et al (1996). Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiological studies. Neurology 47: 425–432.
   PubMed Web of Science ®Google Scholar
• Muir KW, Weir CJ, et al (1999). C-reactive protein and out-come after ischemic stroke. Stroke 30: 981–985.
   PubMed Web of Science ®Google Scholar
• Nakayama M, Uchimura K, et al (1998). Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia. Proc Nati Acad Sci USA 95: 10954–10959.
   PubMed Web of Science ®Google Scholar
• Neuroinflammation Working Group (2000). Inflammation and Alzheimer's disease. Neurobiol Aging 21: 383–421.
   PubMed Web of Science ®Google Scholar
• Nicoll JAR, Mrak RE, et al (2000). Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann Neurol 47: 365–368.
   PubMed Web of Science ®Google Scholar
• Papassotiropoulos A, Bagli M, et al (1999). A genetic vari-ation of the inflammatory cytokine interleukin-6 de-lays the initial onset and reduces the risk for sporadic Alzheimer's disease. Ann Neurol 45: 666–668.
   PubMed Web of Science ®Google Scholar
• Pietila KO, Harmoinen AP, et al (1996). Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur Heart J17: 1345–1349.
   Google Scholar
• Rebeck GW (2000). Confirmation of the genetic association of interleukin-1A with early onset sporadic Alzheimer's disease. Neurosci Lett 293: 75–77.
   PubMed Web of Science ®Google Scholar
• Reynolds WF, Rhees J, et al (1999). Myeloperoxidase poly-morphism is associated with gender specific risk for Alzheimer's disease. Exp Neurol 155: 31–41.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, et al (2000). C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342: 836–843.
   PubMed Web of Science ®Google Scholar
• Rogers J, Cooper NR, et al (1992). Complement activation by /3-amyloid in Alzheimer's disease. Proc Nati Acad Sci USA 89: 10016–10020.
   PubMed Web of Science ®Google Scholar
• Rogers J, Kirby LC, et al (1993). Clinical trial of in-domethacin in Alzheimer's disease. Neurology 43: 1609–1611.
   PubMed Web of Science ®Google Scholar
• Sainati SM, Ingram DM, et al (2000). Results of a double-blind, placebo-controlled study of celecoxib for the progression of Alzheimer's disease. In: Proceedings of 6th International Stockholm-Springfield Symposium of Advances in Alzheimer's Therapy. p 180.
   Google Scholar
• Scharf S, Mander A, et al (1999). A double-blind, placebo-controlled trial of diclofenac misoprostol in Alzheimer's disease. Neurology 53: 197–201.
   PubMed Web of Science ®Google Scholar
• Schwartz CF, Kilgore KS, et al (1999). Increased rat car-diac allograft survival by the glycosaminoglycan pen-tosan polysulfate. J Surg Res 86: 24–28.
   Google Scholar
• Sharif SF, Hariri RJ, et al (1993). Human astrocyte produc-tion of tumour necrosis factor-alpha, interleukin-1 beta, and interleukin-6 following exposure to lipopolysaccha-ride endotoxin. Neurol Res 15: 109–112.
   Web of Science ®Google Scholar
• Stewart WF, Kawas C, et al (1997). Risk of Alzheimer's dis-ease and duration of NSAID use. Neurology 48: 626–632.
   PubMed Web of Science ®Google Scholar
• Strittrnatter WJ, Saunders A, et al (1993). Apolipoprotein E: high avidity binding to /3-amyloid and increased fre-quency of type 4 allele in late-onset familial Alzheimer's disease. Proc Nati Acad Sci USA 90: 1977–1981.
   Google Scholar
• Tanhehco EJ, Kilgore KS, et al (1999). Reduction of my-ocardial infarct size after ischemia and reperfusion by the glycosaminoglycan pentosan polysulfate. J Cardio-vasc Pharmacol 34: 153–161.
   PubMed Web of Science ®Google Scholar
• Van Gool WA, Weinstein HC, et al (2001). Effect of hy-droxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomized, double-blind, placebo-controlled study. Lancet 358: 455–460.
   PubMed Web of Science ®Google Scholar
• Veld BAI, Ruitenberg A, et al (2000). Duration of non-steroidal antiinflammatory drug use and risk of Alzheimer's disease. The Rotterdam study. Neurobiol Aging 21(1S): S204.
   Google Scholar
• Veld BAI, Ruitenberg A, et al (2001). Nonsteroidal antiin-fla=atory drugs and the risk of Alzheimer's disease. New Engl j Med 345: 1515–1521.
   PubMedGoogle Scholar
• Walker DG, Kim SU, et al (1995). Complement and cytokine gene expression in cultured microglia derived from post-mortem human brains. J Neurosci Res 40: 478–493.
   PubMed Web of Science ®Google Scholar
• Wallace JL, Pittman QJ, et al (1995). Nitric oxide-releasing NSAIDs: a novel class of GI-sparing anti-inflammatory drugs. Agents Actions 46(Suppl): 121–129.
   Google Scholar
• Webster S, Bonnell B, et al (1997a). Charge-based binding of complement component C1q to the Alzheimer's amyloid beta-peptide. Am J Pathol 150: 1531–1536.
   PubMedGoogle Scholar
• Webster S, Lue LF, et al (1997b). Molecular and cellu-lar characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol Aging 18: 415–421.
   PubMed Web of Science ®Google Scholar
• Wood JA, Wood PL, et al (1993). Cytokine indices in Alzheimer's temporal cortex: no change in mature IL beta or IL-1RA but increases in the associated acute phase proteins IL-6, alpha 2-macroglobulin and C-reactive protein. Brain Res 629: 245–252.
   PubMed Web of Science ®Google Scholar
• Xia MQ, Qin SX, et al (1998). I=unohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains. Am J Pathol 153: 31–37.
   PubMed Web of Science ®Google Scholar
• Yamabe T, Dhir G, et al (1994). Cytokine-gene expression in measles-infected adult human glial cells. J Neuroim-munol 49: 171–179.
   Google Scholar
• Yasojima K, McGeer EG, et al (1999a). Complement regula-tors Cl inhibitor and CD59 do not significantly inhibit complement activation in Alzheimer's disease. Brain Res 833: 297–301.
   PubMed Web of Science ®Google Scholar
• Yasojima K, Schwab C, et al (1998). Human heart gener-ates complement proteins that are upregulated and ac-tivated after myocardial infarction. Circ Res 83: 860–869.
   PubMed Web of Science ®Google Scholar
• Yasojima K, Schwab C, et al (1999b). Upregulated pro-duction and activation of the complement system in Alzheimer's disease brain. Am J Pathol 154: 927–936.
   PubMed Web of Science ®Google Scholar
• Yasojima K, Schwab C, et al (1999c). Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res 830: 226–236.
   PubMed Web of Science ®Google Scholar
• Yasojima K, Schwab C, et al (2000). Human neurons generate C-reactive protein and amyloid P: upregu-lation in Alzheimer's disease. Brain Res 887: 80–89.
   PubMed Web of Science ®Google Scholar
• Yasojima K, Schwab C, et al (2001). Generation of C-reactive protein and complement components in atherosclerotic plaques. Am j Pathol 158: 1039–1051.
   PubMed Web of Science ®Google Scholar
• Ying SC, Gewurz AT, et al (1993). Human serum amyloid P component oligomers bind and activate the classical complement pathway via residues 14–26 and 76–92 of the A chain collagen-like region of C1q. J Immunol 150: 169–176.
   Google Scholar
• Zlotnik A, Yoshie O (2000). Chemokines: a new classifica-tion system and their role in immunity. Immunity 12: 121–127.
   PubMed Web of Science ®Google Scholar
• Zujovic V, Benavides J, et al (2000). Fractalkine modulates TNF-alpha secretion and neurotoxicity induced by mi-croglial activator. Glia 29: 305–315.
   PubMed Web of Science ®Google Scholar